The latest market report published by Acute Market Reports “Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2020-2028,” the irritable bowel syndrome with diarrhea drugs market was valued at USD 423.3 Mn in 2019, and is expected to reach USD 1,103.1 Mn by 2028, expanding at a CAGR of 11.3% from 2020 to 2028.
Browse the full report Irritable Bowel Syndrome with Diarrhea (IBS-D) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2020–2028 at https://www.acutemarketreports.com/report/irritable-bowel-syndrome-ibs-with-Diarrhea-drugs-market
Market Insights
Irritable bowel syndrome is the most common gastrointestinal disorder which affects the large intestine which is manifested by abdominal cramps, altered peristaltic activity, diarrhea, etc. The major causative agents associated with the repeated occurrence of irritable bowel syndrome associated with diarrhea are severe infection, drug induced, stressful lifestyle, change in gut microbial flora.
Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand for Xifaxan during the forecast period. Drugs such as loperamide will experience a slack in demand due to the introduction of the said novel drugs.
Geographically, North America is the largest market for IBS-D drugs. Higher awareness about the disease, expected prompt availability of the newly approved drugs, better reimbursement system and higher IBS prevalence are the prime factors that drive the IBS-D drugs market in North America. On the other hand, Asia Pacific is expected to be the fastest growing regional market for IBS-D drugs. Japan with its largest pool of geriatric population and with the anticipated approval for Xifaxan in 2018 makes the country the largest national market in Asia Pacific region. In addition, it is also estimated that due to factors such as moderate purchasing power in the patient population, lower diagnosis rates and poor disease awareness will contribute to sustained demand for OTC IBS-D drugs in the region. Regions such as Latin America and MENA are believed to follow the trends in Europe and North America market.
List of Companies Covered:
Key Market Movements:
